A retrospective multicenter study of Enasidenib (ENA) in Older Patients With Relapsed/Refractory Isocitrate Dehydrogenase-2 (IDH2)-Mutated Acute Myeloid Leukemia.

At a glance
Trial Overview
Trial Details
Interventions
Results
- Publications
Authors
Trial History
References

Trial Profile

A retrospective multicenter study of Enasidenib (ENA) in Older Patients With Relapsed/Refractory Isocitrate Dehydrogenase-2 (IDH2)-Mutated Acute Myeloid Leukemia.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enasidenib (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use

Most Recent Events

01 Nov 2022 Results assessing real-world clinical outcomes and healthcare resource use in patients with acute myeloid leukemia, published in the Leukemia Research.
11 Oct 2022 New trial record
01 Oct 2022 Results published in the Clinical Lymphoma, Myeloma & Leukemia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com